Earnings GrowthGeneDx reported third-quarter results that were well ahead of estimates and consensus, with significant revenue growth of 52% year-over-year.
Market ExpansionGeneDx was selected to participate in the Sunshine Genetics Network, the first state-backed newborn screening program, which could enhance its market position.
Revenue GuidanceThe company raised its 2025 revenue guidance, indicating confidence in continued strong performance.